Filing search / Inhibrx Biosciences, Inc. / "Tax"

8-K

EX-99.1

INBX Inhibrx Biosciences, Inc.

24 May 24

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

4:08pm

rates; changes in tax and other laws, regulations, rates and policies; and future business combinations or disposals. Important factors, risks

DEFA14A

INBX Inhibrx Biosciences, Inc.

20 May 24

Additional proxy soliciting materials

9:48pm

or regulatory conditions; the conflicts in the Ukraine and the Middle East; future exchange and interest rates; changes in tax and other laws, regulations, rates

8-K

INBX Inhibrx Biosciences, Inc.

17 May 24

Other Events

5:29pm

and experience) and using a mid-year convention: (i) the forecasted risk-adjusted, after-tax unlevered free cash flows of SpinCo over the period beginning … year (with the exception of platform cash flows for which a 0% perpetuity growth rate was assumed), and (iii) tax savings from usage of SpinCo’s federal

DEFA14A

INBX Inhibrx Biosciences, Inc.

17 May 24

Additional proxy soliciting materials

4:25pm

conditions; the conflicts in the Ukraine and the Middle East; future exchange and interest rates; changes in tax and other laws, regulations, rates

8-K

EX-99.1

INBX Inhibrx Biosciences, Inc.

9 May 24

Inhibrx Reports First Quarter 2024 Financial Results

4:08pm

in Ukraine and the Middle East; future exchange and interest rates; changes in tax and other laws, regulations, rates and policies; and future

8-K

EX-99.1

7y0iprl

8 May 24

Other Events

4:42pm

DEFM14A

hp980uow3w b2ey

26 Apr 24

Proxy related to merger

4:06pm

DEFA14A

q9yd3b 6jwthu

12 Mar 24

Additional proxy soliciting materials

4:05pm

8-K

jxopj

12 Mar 24

Other Events

4:02pm

8-K

EX-99.1

o4c0uo7u 9xtnpknq5x

28 Feb 24

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

9:12am

DEFA14A

b4dqm6n

6 Feb 24

Additional proxy soliciting materials

4:30pm

DEFA14A

9e8rwe4 1p

23 Jan 24

Additional proxy soliciting materials

5:25pm

DEFA14A

efgqm jofjxff6tb

23 Jan 24

Additional proxy soliciting materials

6:38am

8-K

EX-99.1

2tvv2

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

8-K

fos tef3nt2in

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

8-K

EX-2.1

ztrcjfe21 yx

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

8-K

EX-2.2

g00fuwsqa1 1b

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am